Insilico Medicine showcases latest AI drug discovery platform breakthroughs

Insilico Medicine (“Insilico”), an artificial intelligence (AI)-driven, clinical stage biotechnology company and  leader in AI drug discovery platform technology, is hosting three webinars unveiling its latest technology breakthroughs Nov. 28-30, 2023. These new features are part of the expansion of the Company’s end-to-end Pharma.AI platform and include chat functionality, off-target screening tools, enhanced knowledge graphs and more. They represent major steps forward in the advancement of AI drug discovery.

The company is an early innovator in generative chemistry and biology and founder and co-CEO Alex Zhavoronkov, PhD first began publishing on the use of algorithms to find biomarkers for aging and disease in 2014, the same year Insilico was founded. By 2016, he had published the first peer-reviewed paper on generative chemistry, applying GANs to generate novel small molecules against cancer.

This early research gave rise to the company’s end-to-end platform – Pharma.AI – built on massive quantities of publicly available data and connecting that data to diseases and biological processes in order to identify novel targets, design new drugs, and predict the outcome of clinical trials.

This platform is now used by over 40 leading pharma companies, and has produced an internal pipeline of 31 therapeutic assets across 29 targets, including in cancer, fibrosis, and central nervous system diseases, with four in clinical stages. The Company’s lead drug, designed to treat idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II trials with patients. Another drug developed by this platform – a potentially best-in-class USP1 cancer inhibitor for BRCA-mutated tumors – was recently licensed to Exelixis for $80m upfront and additional milestone and royalty payments.

Pharma.AI Platform Webinars: 

PandaOmics 4.0 Webinar – On Nov. 28, 9am ET,  Insilico will unveil the latest updates to ita AI target discovery engine, PandaOmics, including chat functionality, genetics related enhancements, indication prioritization and more. Online here: https://insilico.zoom.us/webinar/register/1016970290536/WN_zuuUT4poRvSNFxVWZTa9pw#/registration

Chemistry42 3.0 Webinar – On Nov. 29, 9am ET, Insilico will showcase new features for the Company’s generative AI drug design engine, Chemistry42, including ADMET optimization, a Golden Cubes feature which runs virtual kinases panels on databases of small molecules for off-target screening, custom reward modules, and more. Online here: https://insilico.zoom.us/webinar/register/1716970361580/WN_tm6N9ae2SuOcYxxBxjyMdg#/registration

InClinico 2.0 Webinar – On Nov. 30. 9am ET, Insilico will reveal the latest updates to the Compan’s AI clinical trial prediction tool, inClinico, including the predictive probability of success score, chat functionality, and network graph for target choice, among other features. Online here: https://insilico.zoom.us/webinar/register/8416970337545/WN_WzR6MJyISxWs9pW2cvl89A#/registration

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com

Media Contact

Brita Belli
Insilico Medicine
brita@insilico.com
Office: 475-225-0843
 @InsilicoMeds

www.insilico.com